Exclusive Summary

• - Patents expired long ago with wide generic entry; registration pathways are mature for rapid distribution launches.
• - Around 150k solid organ transplants occur annually and 1.5–2.5 million recipients require lifelong therapy, with added demand from lupus nephritis and other IMIDs.
• - MMF is a core component of standard triple maintenance in transplants, listed on the WHO EML and recommended as first-line/ preferred in major guidelines.
• - The 250 mg capsule enables dose titration and pediatric/small-body-weight use, fitting tender requirements and prescribing habits across markets.
• - Using China retail prices, generics are ~80–90%+ cheaper than originator; at 2 g/day annual cost can drop from about $4,450 to ~$460, driving strong tender and payer appeal.